Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment approach consisting of dendritic cell (DC) vaccination to prime tumor-specific T cells, and a strategy to reprogram the desm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Lau, Sai Ping, van Montfoort, Nadine, Kinderman, Priscilla, Lukkes, Melanie, Klaase, Larissa, van Nimwegen, Menno, van Gulijk, Mandy, Dumas, Jasper, Mustafa, Dana A M, Lievense, Sanne L A, Groeneveldt, Christianne, Stadhouders, Ralph, Li, Yunlei, Stubbs, Andrew, Marijt, Koen A, Vroman, Heleen, van der Burg, Sjoerd H, Aerts, Joachim, van Hall, Thorbald, Dammeijer, Floris, van Eijck, Casper H J
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7373331/
https://ncbi.nlm.nih.gov/pubmed/32690771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000772
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars